
LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
A glimpse at what to expect from Dermatology Times this week.
Some of the content the staff at Dermatology Times will be publishing this week includes:
New articles from our May issue;
More news coming out of the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021).
Plus more!






